MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gould, R. J.
Right arrow Articles by Snyder, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gould, R. J.
Right arrow Articles by Snyder, S. H.

Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine

RJ Gould, KM Murphy and SH Snyder

Calcium channel antagonist binding sites have been labeled in cerebral cortex, heart, ileum, and skeletal muscle with [3H]nitrendipine. While the dissociation constants of the site from cortex, heart, and ileum are similar, KD approximately equal to 0.1-0.2 nM, the value in skeletal muscle is 2 nM. This difference is affinity is also reflected in the Ki values of dihydropyridine calcium channel antagonists, nifedipine, nimodipine, PY108068, SKF24260, and nisoldipine, and the calcium channel agonist CGP 28392, all of which show lower affinity for the skeletal muscle binding site. The diphenylalkylamine calcium channel antagonists, lidoflazine, cinnarizine, flunarizine, and prenylamine, however, show a 3- to 10-fold increase in affinity in skeletal muscle relative to the other three tissues. EDTA treatment of membranes decreases binding in cortex, heart, and ileum but increases binding in skeletal muscle. These changes are reversible upon addition of CaCl2, SrCl2, or BaCl2. The different properties of [3H]nitrendipine binding in various tissues may relate to the varying tissue sensitivity to organic calcium channel antagonists.

Volume 25, Issue 2, pp. 235-241, 03/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 HypertensionHome page
M. Mahata, S. K. Mahata, R. J. Parmer, and D. T. O'Connor
Vesicular Monoamine Transport Inhibitors: Novel Action at Calcium Channels to Prevent Catecholamine Secretion
Hypertension, September 1, 1996; 28(3): 414 - 420.
[Abstract] [Full Text]

Home page
 ScienceHome page
M Takahashi and W. Catterall
Identification of an alpha subunit of dihydropyridine-sensitive brain calcium channels
Science, April 3, 1987; 236(4797): 88 - 91.
[Abstract] [PDF]

Home page
 ScienceHome page
R. Miller
Multiple calcium channels and neuronal function
Science, January 2, 1987; 235(4784): 46 - 52.
[Abstract] [PDF]

Home page
 ScienceHome page
J. Wagner, I. Reynolds, H. Weisman, P Dudeck, M. Weisfeldt, and S. Snyder
Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain
Science, April 25, 1986; 232(4749): 515 - 518.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics